
1. vaccine. 2017 apr 25;35(18):2463-2472. doi: 10.1016/j.vaccine.2017.03.023. epub
2017 mar 22.

generation, characterization immunogenicity novel chimeric recombinant
protein based plasmodium vivax ama-1 msp119.

rocha mv(1), françoso ks(1), lima lc(1), camargo tm(1), machado rld(2), costa
ftm(3), rénia l(4), nosten f(5), russell b(6), rodrigues mm(7), soares is(8).

author information: 
(1)departamento de análises clínicas e toxicológicas, faculdade de ciências
farmacêuticas, universidade de são paulo, são paulo, sp, brazil.
(2)divisão de parasitologia, instituto evandro chagas, belém, pa, brazil.
(3)laboratório de doenças tropicais - departamento de genética, evolução e
bioagentes, instituto de biologia, universidade estadual de campinas, campinas,
sp, brazil.
(4)singapore immunology network, biopolis, agency science technology and
research, singapore.
(5)shoklo malaria research unit, mahidol-oxford tropical medicine research unit, 
faculty tropical medicine, mahidol university, mae sot, thailand; centre for
tropical medicine global health, nuffield department medicine research
building, university oxford old road campus, oxford, uk.
(6)singapore immunology network, biopolis, agency science technology and
research, singapore; department microbiology immunology, university of
otago, dunedin, new zealand.
(7)ctcmol, departamento de microbiologia, imunologia e parasitologia,
universidade federal de são paulo-escola paulista de medicina, são paulo, sp,
brazil.
(8)departamento de análises clínicas e toxicológicas, faculdade de ciências
farmacêuticas, universidade de são paulo, são paulo, sp, brazil. electronic
address: isoares@usp.br.

plasmodium vivax widely distributed malaria species most
prevalent species malaria america asia. vaccine development p. 
vivax considered priority global program eradication of
malaria. earlier studies characterized apical membrane antigen 1 (ama-1)
ectodomain c-terminal region (19kda) merozoite surface protein 1
(msp-1) p. vivax immunodominant antigens. based characterization,
we designed chimeric recombinant protein containing merozoite
immunodominant domains (pvama166-msp119). recombinant pvama166-msp119 was
successfully expressed pichia pastoris used immunize two different
mouse strains (balb/c c57bl/6) presence poly (i:c) an
adjuvant. immunization chimeric protein induced high antibody titers
against proteins strains mice detected elisa. antisera also
recognized native proteins expressed merozoites mature p. vivax
schizonts. moreover, antigen able induce ifn-gamma-secreting cells in
c57bl/6 mice. findings indicate novel yeast recombinant protein
containing pvama166 pvmsp119 advantageous, improved antibody
titers cellular immune response. therefore, formulation be
further developed pre-clinical trials non-human primates potential
candidate p. vivax vaccine.

copyright © 2017 elsevier ltd. rights reserved.

doi: 10.1016/j.vaccine.2017.03.023 
pmid: 28341111  [indexed medline]

